Published 10 days ago • loading... • Updated 10 days ago
Mammoth Biosciences Advances Lead Candidate MB-111 Toward the Clinic with the Presentation of Preclinical Durability and Safety Data at American Heart Association Scientific Sessions 2026
BRISBANE, Calif.--(BUSINESS WIRE)-- #AHA--Durable efficacy and favorable safety profile supports planned 2027 clinical testing in persistent chylomicronemia.
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.